| Breast Cancer |
1 |
1 |
| Breast Cancer Screening |
0 |
0.81 |
| Cancer |
0 |
0.7 |
| Colorectal Cancer |
0 |
0.62 |
| Breast |
0 |
0.61 |
| Cervical Cancer |
0 |
0.6 |
| Liquid Biopsy |
0 |
0.53 |
| Colorectal Cancer Screening |
0 |
0.51 |
| Colon Cancer |
0 |
0.5 |
| Mammogram |
0 |
0.28 |
| Preventive Screening |
0 |
0.27 |
| Clinical Guidelines |
0 |
0.1 |
| Tumor |
0 |
0.08 |
| Biopsy |
0 |
0.03 |
| CT Scan |
0 |
0.03 |
| Proteomics |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |
| Ultrasonography |
0 |
0.03 |
| Blood |
0 |
0.02 |
| Bowel Preparation |
0 |
0.02 |
| Cardiovascular Risk Management |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Colonoscopy |
0 |
0.02 |
| Healthcare and Medical Technology |
0 |
0.02 |
| Heart |
0 |
0.02 |
| Osteoporosis |
0 |
0.02 |
| Receptors |
0 |
0.02 |
| Selective Estrogen Receptor Modulators |
0 |
0.02 |
| Adherence |
0 |
0.01 |
| Aspiration |
0 |
0.01 |
| Biomarker |
0 |
0.01 |
| Bone |
0 |
0.01 |
| Cardiovascular disease |
0 |
0.01 |
| Chemotherapy |
0 |
0.01 |
| Ductal carcinoma in situ |
0 |
0.01 |
| Estrogen |
0 |
0.01 |
| Europe |
0 |
0.01 |
| Health Equity |
0 |
0.01 |
| Insurance |
0 |
0.01 |
| Magnetic Resonance Imaging |
0 |
0.01 |
| Medical Life |
0 |
0.01 |
| New York |
0 |
0.01 |
| Prognosis |
0 |
0.01 |
| Revenue and Practice Management |
0 |
0.01 |
| Rural Health |
0 |
0.01 |
| Sexual Dysfunction |
0 |
0.01 |
| Socioeconomics |
0 |
0.01 |
| Women in Medicine |
0 |
0.01 |